A second opinion on the need for new warnings on attention deficit hyperactivity disorder (ADHD) drugs from the FDA advisory committee contradicts The Pediatric Advisory Committee recommendation.

ADHD Drugs: Label Cautions, but No Black Box

According to recent estimates,chronic medical conditionsaccount for 7 of every 10 deathsin the United States and have been foundto severely limit daily functioning in morethan 1 of 10 Americans, or 25 millionpeople This tremendous disease burdenaccounts for most of the dollars spenton health care annually in the UnitedStates.

Psychiatric Times Vol 23 No 5